DR. LAL PATH LABS LTD.

Dr. Lal PathLabs reported strong operational performance in its Q1 FY27 earnings conference call, achieving a revenue of Rs. 798 crore, reflecting a year-on-year growth of 19.1%, the highest quarterly growth in four years. Management attributed this growth to increased patient volumes and sample volumes, which rose by 8.2% and 10.7%, respectively. The company emphasized its commitment to expanding its rural outreach program, which has tested over 110,000 patients in seven states. Additionally, management highlighted the launch of new tests and advancements in digital infrastructure to enhance patient experience. EBITDA grew by 28.7% to Rs. 247 crore, with a margin of 31%. The company also announced an interim dividend of 50%. Management expressed confidence in maintaining sustainable growth, supported by structural volume tailwinds and a focus on high-end specialized tests. The call included discussions on acquisitions and the company's international expansion plans.

Management highlighted strong growth and strategic initiatives during the earnings call.